Press Releases

Date	Title	Company
12-Dec-2022	Cardiovascular Needle Market Poised to Rake in US$ 188.4 Mn by 2032 \| FMI	MARKITWIRED
12-Dec-2022	Chemotherapy Induced Anemia Market Size to Reach US$ 4.3 Bn by 2032 \| CAGR of 7.2%	MARKITWIRED
12-Dec-2022	Orphan Drugs Market worth US$ 267.6 billion by 2032 – Exclusive Report by Future market insights	MARKITWIRED
12-Dec-2022	Home Rehabilitation Services Market slated to increase at a CAGR of 4.8%, to reach US$ 140.5 Bn by 2032	MARKITWIRED
12-Dec-2022	Nuclear Medicine (Radiopharmaceuticals) Market is geared to grow at a CAGR of 12.5% from 2023 to 2032 \| insightSLICE	insightSLICE
12-Dec-2022	Orthodontics Market is projected to accelerate at a CAGR of 16% from 2023 to 2032 \| insightSLICE	insightSLICE
12-Dec-2022	Electrophysiology Devices Market is geared to grow at a CAGR of 10% from 2023 to 2032 \| insightSLICE	insightSLICE
12-Dec-2022	Healthcare EDI Market is anticipated to expand at a CAGR of 9% from 2023 to 2032 \| insightSLICE	insightSLICE
12-Dec-2022	Incontinence Care Products Market to achieve CAGR of 6.1% from 2023 to 2032 \| insightSLICE	insightSLICE
12-Dec-2022	First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)	Businesswire
12-Dec-2022	Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma	Enterome
12-Dec-2022	FORXIGA (dapagliflozin) APPROVED IN GREAT BRITAIN FOR SYMPTOMATIC CHRONIC HEART FAILURE ACROSS THE FULL SPECTRUM OF LEFT VENTRICULAR EJECTION FRACTION	AstraZeneca
12-Dec-2022	Heart surgery and impact on mental health among new national priorities for congenital heart disease research	University of Birmingham
12-Dec-2022	NICE process “not appropriate for a rapidly evolving virus”	Kidney Research UK
12-Dec-2022	CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma	CellCentric
12-Dec-2022	Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner	Novozymes and Chr. Hansen
12-Dec-2022	POLB 001 LPS human challenge clinical trial successfully completed No serious adverse events reported	Poolbeg Pharma plc
12-Dec-2022	OSE Immunotherapeutics Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting	OSE Immunotherapeutics
12-Dec-2022	New Clinical Data For Zanidatamab In HER2+ /HR+ Metastatic Breast Cancer Presented Today At 2022 SABCS	Zymeworks Inc.
12-Dec-2022	Glucose Sensor Market reaching around US$ 16,382 million by the end of 2032 \| FMI	MARKITWIRED